[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES]
CALGARY, AB / ACCESSWIRE / May 24, 2024 / Asia Green Biotechnology Corp. (“Asia Green” or the “Company”) (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, May 8, 2024, and May 10, 2024, the Company has filed the following continuous disclosure documents (collectively, the “Documents”) on SEDAR:
It is expected that the Management Cease Trade Order (“MCTO”) issued by the Alberta Securities Commission (“ASC”) on May 8, 2024, will now be lifted.
In addition, the Company also announced today that Vincent Ghazar has resigned from his positions as Chief Financial Officer and Director of the Company. Mr. Ghazar will remain with the Company as a consultant providing accountancy services in the near term.
For further information, contact:
Asia Green Biotechnology Corp.
David Pinkman (CEO)
T: 403 863-6034
E: david.pinkman@asiagreenbiotechnology.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Asia Green Biotechnology Corp.
View the original press release on accesswire.com
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…
LegitScript-certified telehealth platform publishes consumer analysis as searches for GLP-1 weight loss information reach record…
Independent investigation examines castor oil, tea tree oil, and salicylic acid formulation claims in the…
Independent examination investigates SleepZee's moldable customization approach, medical-grade material claims, and manufacturer disclosure practices for…
Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving…